ANKEF1: A Potential Drug Target for A Variety of Disorders (G63926)

Target Name: ANKEF1

NCBI ID: G63926

ANKEF1

ANKEF1: A Potential Drug Target for A Variety of Disorders

ANKEF1 (dJ839B4.6) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 8 and has been shown to play a role in the development and progression of several diseases, including neurodegenerative disorders, autoimmune diseases, and psychiatric disorders.

ANKEF1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells in the body. It is primarily expressed in the brain and has been shown to play a role in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The gene is also expressed in other tissues, including the heart, lungs, and kidneys.

One of the key features of ANKEF1 is its ability to interact with several different proteins, including the protein known as TDP-4, which is a key regulator of the DNA double helix. The interaction between ANKEF1 and TDP-4 has been shown to play a role in the regulation of gene expression and the development of neurodegenerative disorders.

In addition to its role in neurodegenerative disorders, ANKEF1 has also been shown to be involved in the development and progression of other diseases, including autoimmune diseases and psychiatric disorders. For example, studies have shown that ANKEF1 is expressed in the brains of individuals with multiple sclerosis, an autoimmune disease that causes muscle weakness and stiffness.

Furthermore, ANKEF1 has also been shown to be involved in the regulation of sleep and wake cycles, which is a critical aspect of brain function that is often disrupted in disorders such as sleep apnea and insomnia.

The potential drug targets for ANKEF1 are vast and varied. For example, ANKEF1 has been shown to play a role in the development of neurodegenerative disorders, so drugs that can inhibit the activity of TDP-4 and other proteins that interact with ANKEF1 may be a potential treatment for these disorders. Additionally, ANKEF1 has also been shown to be involved in the regulation of sleep and wake cycles, so drugs that can modulate brain activity during these processes may be a potential treatment for disorders such as sleep apnea and insomnia.

In conclusion, ANKEF1 is a gene that has been shown to play a role in the development and progression of a variety of diseases, including neurodegenerative disorders, autoimmune diseases, and psychiatric disorders. Its potential drug targets are vast and varied, and further research is needed to fully understand its role in the development and treatment of these disorders.

Protein Name: Ankyrin Repeat And EF-hand Domain Containing 1

The "ANKEF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKEF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets